Physician profile
Lawrence T Wang
NPI 1417920216
$4,836.73
in general payments reported to CMS, 2019-2025
24 companies · $2,808 in 2025
The $2,808 reported for 2025 was more than what 83% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.94 · 2022: $46.16 · 2023: $314 · 2024: $1,601 · 2025: $2,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,652 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,651.63 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $872.75 | 2024-2025 | |
| Ucb, INC. | $715.63 | 2023-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $592.51 | 2019-2025 | Rinvoq |
| Incyte Corporation | $385.91 | 2024-2025 | Opzelura |
| Leo Pharma INC. | $385.54 | 2023-2025 | Adbry, Anzupgo |
| Pfizer INC. | $273.92 | 2022-2025 | |
| Janssen Biotech, INC. | $244.06 | 2024-2025 | Tremfya |
| Amgen INC. | $243.24 | 2023-2025 | Otezla, Otezla |
| Lilly USA, LLC | $233.89 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $146.74 | 2024-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $121.69 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $108.67 | 2024-2025 | Zoryve |
| Galderma Laboratories, L.P. | $93.99 | 2024-2025 | Nemluvio, Aklief |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.50 | 2023-2025 | Spevigo |
| Smith+Nephew, INC. | $63.09 | 2024 | Stravix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $57.38 | 2024 | Vtama |
| Convatec INC. | $55.92 | 2024-2025 | |
| Integra Lifesciences Corporation | $43.67 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Almirall LLC | $34.97 | 2019-2024 | Klisyri |
| Chiesi USA, INC. | $25.84 | 2024 | Filsuvez |
| Kerecis Limited | $20.98 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Novartis Pharmaceuticals Corporation | $17.11 | 2025 | |
| Merck Sharp & Dohme LLC | $15.04 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.69 | 2024 | Sotyktu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.